User menu

MRI for response assessment in metastatic bone disease.

Bibliographic reference Lecouvet, Frédéric ; Larbi, Ahmed ; Pasoglou, Vasiliki ; Omoumi, Patrick ; Tombal, Bertrand ; et. al. MRI for response assessment in metastatic bone disease.. In: European Radiology : journal of the European Congress of Radiology, Vol. 23, no.7, p. 1986-97 (2013)
Permanent URL
  1. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  2. Scher Howard I., Morris Michael J., Basch Ethan, Heller Glenn, End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice, 10.1200/jco.2011.35.8648
  3. Gosfield E 3rd, Alavi A, Kneeland B (1993) Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 34:2191–2198
  4. Lecouvet Frédéric E., Geukens Daphné, Stainier Annabelle, Jamar François, Jamart Jacques, d'Othée Bertrand Janne, Therasse Patrick, Berg Bruno Vande, Tombal Bertrand, Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies, 10.1200/jco.2006.09.2940
  5. Çiray I., Åström G., Andréasson I., Edekling T., Hansen J., Bergh J., Ahlström H., Evaluation of new sclerotic bone metastases in breast cancer patients during treatment, 10.1080/028418500127345019
  6. Messiou C, Cook G, deSouza N M, Imaging metastatic bone disease from carcinoma of the prostate, 10.1038/sj.bjc.6605334
  7. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297
  8. Galasko CS (1995) Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res 312:64–75
  9. Hamaoka Tsuyoshi, Madewell John E., Podoloff Donald A., Hortobagyi Gabriel N., Ueno Naoto T., Bone Imaging in Metastatic Breast Cancer, 10.1200/jco.2004.08.181
  10. Lecouvet Frederic E., Malghem Jacques, Michaux Lucienne, Maldague Baudouin, Ferrant Augustin, Michaux Jean-Louis, Vande Berg Bruno C., Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey, 10.1046/j.1365-2141.1999.01529.x
  11. Moulopoulos L A, Dimopoulos M A, Alexanian R, Leeds N E, Libshitz H I, Multiple myeloma: MR patterns of response to treatment., 10.1148/radiology.193.2.7972760
  12. Groves Ashley M., Beadsmoore Clare J., Cheow Heok K., Balan Kottekkattu K., Courtney Helen M., Kaptoge Stephen, Win Thida, Harish Srinivasan, Bearcroft Philip W. P., Dixon Adrian K., Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient, 10.1007/s00330-005-0042-z
  13. Bäuerle Tobias, Semmler Wolfhard, Imaging response to systemic therapy for bone metastases, 10.1007/s00330-009-1443-1
  14. Yang Hui-Lin, Liu Tao, Wang Xi-Ming, Xu Yong, Deng Sheng-Ming, Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy, 10.1007/s00330-011-2221-4
  15. Antoch Gerald, Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology, 10.1001/jama.290.24.3199
  16. Stafford Stephanie E., Gralow Julie R., Schubert Erin K., Rinn Kristine J., Dunnwald Lisa K., Livingston Robert B., Mankoff David A., Use of Serial FDG PET to Measure the Response of Bone-Dominant Breast Cancer to Therapy, 10.1016/s1076-6332(03)80461-0
  17. Tateishi Ukihide, Gamez Cristina, Dawood Shaheenah, Yeung Henry W. D., Cristofanilli Massimo, Macapinlac Homer A., Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT, 10.1148/radiol.2471070567
  18. De Giorgi U., Mego M., Rohren E. M., Liu P., Handy B. C., Reuben J. M., Macapinlac H. A., Hortobagyi G. N., Cristofanilli M., Ueno N. T., 18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer, 10.2967/jnumed.110.076455
  19. Du Yong, Cullum Ian, Illidge Tim M., Ell Peter J., Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer, 10.1200/jco.2007.11.2854
  20. Shankar LK, Hoffman JM, Bacharach S et al (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059–1066
  21. Vande Berg B. C., Lecouvet F. E., Michaux L., Ferrant A., Maldague B., Malghem J., Magnetic resonance imaging of the bone marrow in hematological malignancies, 10.1007/s003300050548
  22. Daldrup-Link Heike E., Franzius Christiane, Link Thomas M., Laukamp Daniela, Sciuk Joachim, Jürgens Heribert, Schober Otmar, Rummeny Ernst J., Whole-Body MR Imaging for Detection of Bone Metastases in Children and Young Adults : Comparison with Skeletal Scintigraphy and FDG PET, 10.2214/ajr.177.1.1770229
  23. Ghanem N., Uhl M., Brink I., Schäfer O., Kelly T., Moser E., Langer M., Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone, 10.1016/j.ejrad.2005.01.016
  24. Schmidt Gerwin P., Schoenberg Stefan O., Schmid Rupert, Stahl Robert, Tiling Reinhold, Becker Christoph R., Reiser Maximilian F., Baur-Melnyk Andrea, Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT, 10.1007/s00330-006-0361-8
  25. Vande Berg Bruno C., Lecouvet Frédéric E., Galant Christine, Maldague Baudouin E., Malghem Jacques, Normal Variants and Frequent Marrow Alterations that Simulate Bone Marrow Lesions at MR Imaging, 10.1016/j.rcl.2005.01.007
  26. Tombal Bertrand, Rezazadeh Afshin, Therasse Patrick, Van Cangh Paul J., Vande Berg Bruno, Lecouvet Frédéric E., Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, 10.1002/pros.20280
  27. Lecouvet F. E., Simon M., Tombal B., Jamart J., Vande Berg B. C., Simoni P., Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), 10.1007/s00330-010-1879-3
  28. Lecouvet Frédéric E., El Mouedden Jawad, Collette Laurence, Coche Emmanuel, Danse Etienne, Jamar François, Machiels Jean-Pascal, Vande Berg Bruno, Omoumi Patrick, Tombal Bertrand, Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?, 10.1016/j.eururo.2012.02.020
  29. Schmidt Gerwin P., Reiser Maximilian F., Baur-Melnyk Andrea, Whole-body MRI for the staging and follow-up of patients with metastasis, 10.1016/j.ejrad.2009.03.045
  30. Baur-Melnyk Andrea, Buhmann Sonja, Becker Christoph, Schoenberg Stefan Oswald, Lang Nicola, Bartl Reiner, Reiser Maximilian Ferdinand, Whole-Body MRI Versus Whole-Body MDCT for Staging of Multiple Myeloma, 10.2214/ajr.07.2635
  31. Lecouvet Frédéric E., De Nayer Pierre, Garbar Christian, Noël Henri, Malghem Jacques, Maldague Baudouin E., Vande Berg Bruno C., Treated plasma cell lesions of bone with MRI signs of response to treatment: unexpected pathological findings, 10.1007/s002560050461
  32. Malghem J, Vande Berg B, Noël H, Maldague B (1995) Imagerie de la moelle normale et de ses variations. In: S. Sintzoff, J.D Laredo, M. Caroit (eds) Imagerie de l’os et de la moelle osseuse, Getroa Opus XXII, Sauramps Medical Montpellier pp 123–134
  33. Hwang Sinchun, Panicek David M., Magnetic resonance imaging of bone marrow in oncology, Part 2, 10.1007/s00256-007-0308-4
  34. Ryan S P, Weinberger E, White K S, Shaw D W, Patterson K, Nazar-Stewart V, Miser J, MR imaging of bone marrow in children with osteosarcoma: effect of granulocyte colony-stimulating factor., 10.2214/ajr.165.4.7545864
  35. Çiray I., Lindman H., Åström K.G.O., Bergh J., Ahlström K.H., Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging, 10.1080/028418501127346503
  36. Saip Pinar, Tenekeci Nuri, Aydiner Adnan, Dinçer Maktav, lnanç Sevil, Demir Cumhur, Oral E. N., Topuz Erkan, Response Evaluation of Bone Metastases in Breast Cancer: Value of Magnetic Resonance Imaging, 10.3109/07357909909032842
  37. Padhani Anwar R., Koh Dow-Mu, Diffusion MR Imaging for Monitoring of Treatment Response, 10.1016/j.mric.2010.10.004
  38. Lecouvet Frédéric E., Vande Berg Bruno C., Malghem Jacques, Omoumi Patrick, Simoni Paolo, Diffusion-weighted MR Imaging: Adjunct or Alternative to T1-weighted MR Imaging for Prostate Carcinoma Bone Metastases?, 10.1148/radiol.2522090263
  39. KOH Dow-Mu, TAKAHARA Taro, IMAI Yutaka, COLLINS David J, Practical Aspects of Assessing Tumors Using Clinical Diffusion-weighted Imaging in the Body, 10.2463/mrms.6.211
  40. Charles-Edwards Elizabeth M, Diffusion-weighted magnetic resonance imaging and its application to cancer, 10.1102/1470-7330.2006.0021
  41. Reischauer Carolin, Froehlich Johannes M., Koh Dow-Mu, Graf Nicole, Padevit Christian, John Hubert, Binkert Christoph A., Boesiger Peter, Gutzeit Andreas, Bone Metastases from Prostate Cancer: Assessing Treatment Response by Using Diffusion-weighted Imaging and Functional Diffusion Maps—Initial Observations, 10.1148/radiol.10092469
  42. Messiou C., Collins D. J., Giles S., de Bono J. S., Bianchini D., de Souza N. M., Assessing response in bone metastases in prostate cancer with diffusion weighted MRI, 10.1007/s00330-011-2173-8
  43. Koh Dow-Mu, Blackledge Matthew, Collins David J., Padhani Anwar R., Wallace Toni, Wilton Benjamin, Taylor N. Jane, Stirling J. James, Sinha Rajesh, Walicke Pat, Leach Martin O., Judson Ian, Nathan Paul, Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial, 10.1007/s00330-009-1469-4
  44. Vassiliou V., Andreopoulos D., Frangos S., Tselis N., Giannopoulou E., Lutz S., Bone Metastases: Assessment of Therapeutic Response through Radiological and Nuclear Medicine Imaging Modalities, 10.1016/j.clon.2011.03.010
  45. Biffar Andreas, Sourbron Steven, Schmidt Gerwin, Ingrisch Michael, Dietrich Olaf, Reiser Maximilian F., Baur-Melnyk Andrea, Measurement of perfusion and permeability from dynamic contrast-enhanced MRI in normal and pathological vertebral bone marrow, 10.1002/mrm.22415
  46. O'Connor J P B, Jackson A, Parker G J M, Jayson G C, DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents, 10.1038/sj.bjc.6603515
  47. Bauerle T., Merz M., Komljenovic D., Zwick S., Semmler W., Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study, 10.1158/1078-0432.ccr-09-2932
  48. Tofts Paul S., Brix Gunnar, Buckley David L., Evelhoch Jeffrey L., Henderson Elizabeth, Knopp Michael V., Larsson Henrik B.W., Lee Ting-Yim, Mayr Nina A., Parker Geoffrey J.M., Port Ruediger E., Taylor June, Weisskoff Robert M., Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols, 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>;2-s